-- ZYUS Life Sciences' (ZYUS.V) patent, held by its wholly owned unit, ZYUS Life Sciences Inc., was issued by the United States Patent and Trademark Office (USPTO) (U.S. Patent No. 12,616,704,) entitled "CANNABICHROMENE FORMULATION FOR PAIN MANAGEMENT," it said overnight Tuesday.
The patent is based on International Patent Application No. PCT/CA2021/050430 and covers a novel, non-intoxicating approach to pain management, it said. The newly issued patent relates to the company's second drug candidate, further expanding its pipeline of novel, proprietary, non-opioid therapies and supports ongoing clinical research targeting neuropathic pain, including peripheral neuropathy, such as diabetic and cancer-related neuropathies, it added.
The patent provides additional intellectual property protection alongside potential regulatory exclusivity for CBC, whether as monotherapy or within its lead drug product, Trichomylin softgel capsules, subject to regulatory determination by the U.S. Food and Drug Administration at the time of marketing authorization.
"The issuance of this U.S. patent further validates our commitment to advancing a differentiated portfolio of novel non-opioid pain drugs," said ZYUS Chief Executive Brent Zettl. "We remain focused on developing innovative treatment options to address significant unmet needs in chronic and neuropathic pain."
Shares of the company were last seen unchanged at $0.45 on the TSX Venture Exchange.